Novartis key multiple sclerosis drug Gilenya® approved by China NMPA
Basel: Chinese National Medical Products Administration (NMPA) approved Novartis's drug Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older.
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date[1].
"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent® demonstrate our commitment to Chinese patients. We are proud that Gilenya already demonstrated its benefits to over 283,000 MS patients worldwide. We are committed to bringing innovation to China with our key brands Entresto, Cosentyx and now Gilenya." said Marie-France Tschudin, President, Novartis Pharmaceuticals.
Novartis has shown commitment to bringing innovation to China and to reimagining care for patients. Entresto® was approved in 2017. Following the approval of Cosentyx® in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China.
Read Also: Novartis sickle cell drug crizanlizumab secures speedy USFDA review
"I am delighted that we can now offer Gilenya to doctors and patients in China. There is a considerable need for MS treatments in China and we strive to bring clinical benefit to many patients with multiple sclerosis and improve their quality of life," said Ingrid Zhang, President, Novartis Pharmaceuticals China.
Read Also: CDSCO Committee turns down Novartis FDC drug including Vildagliptin, Metformin, Glimepiride
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves
Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date[1].
"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent® demonstrate our commitment to Chinese patients. We are proud that Gilenya already demonstrated its benefits to over 283,000 MS patients worldwide. We are committed to bringing innovation to China with our key brands Entresto, Cosentyx and now Gilenya." said Marie-France Tschudin, President, Novartis Pharmaceuticals.
Novartis has shown commitment to bringing innovation to China and to reimagining care for patients. Entresto® was approved in 2017. Following the approval of Cosentyx® in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China.
Read Also: Novartis sickle cell drug crizanlizumab secures speedy USFDA review
"I am delighted that we can now offer Gilenya to doctors and patients in China. There is a considerable need for MS treatments in China and we strive to bring clinical benefit to many patients with multiple sclerosis and improve their quality of life," said Ingrid Zhang, President, Novartis Pharmaceuticals China.
Read Also: CDSCO Committee turns down Novartis FDC drug including Vildagliptin, Metformin, Glimepiride
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system).In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd